Company news
Sernova Biotherapeutics Inc news in 2021
Sernova Biotherapeutics Inc's news releases, calls and decks from 2021, newest first.
Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium
December 16, 2021
Sernova Appoints Christopher Barnes as Vice President, Investor Relations & Grants Options/DSUs
December 14, 2021
Sernova Announces Appointment of Executive Chair to Complement its Management Team
December 2, 2021
Sernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
November 16, 2021
Sernova: The Ultimate Combination of Two Proven Technologies as Potential Functional Cure for Type 1 Diabetes and Other Chronic Diseases
October 1, 2021
Sernova Engages New York-Based LifeSci Advisors as US Investor Relations Partner
September 29, 2021
Sernova Signs Collaboration Agreement to Advance Conformal Coated Immune Protected Therapeutic Cells for Diabetes with the University of Miami
September 16, 2021
Sernova to Present Corporate Update at Canaccord Genuity's 41st Annual Growth Conference
August 9, 2021
Sernova Announces 2021 Annual Meeting Results: Shareholders Approve Resolutions with Overwhelming Majority
July 5, 2021
Industry Veteran Frank Shannon Joins Sernova as VP Clinical Development and Regulatory Affairs
June 30, 2021
Sernova's Principal Investigator Presents Interim Data and Positive Patient Outcomes of Phase I/II T1D Study at the American Diabetes Association 81st Scientific Sessions
June 28, 2021
Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference
June 7, 2021
Sernova Announces American Transplant Congress 2021 Virtual Connect Abstract Presentation
June 1, 2021
Sernova to Present at Global Partnership Family Office -- HealthCare & Biotechnology TSX Showcase
May 17, 2021
Sernova Announces the Nomination of Seasoned Pharma Executive Dr. Mohammad Azab to its Board of Directors
May 4, 2021
Sernova KOL Event Highlights Novel Cell Therapy Approach for the Potential Treatment of Thyroid Disease
April 28, 2021
Sernova to Host a Virtual Key Opinion Leader Event on Thyroid Disease and the Potential for its Cell Therapy as a Novel Treatment Approach
April 21, 2021
Sernova Appoints Internationally Renowned Thyroid Disease Expert Dr. Sam Wiseman to its Scientific Advisory Board
April 14, 2021
Sernova Announces Presentation at the American Diabetes Association 81st Scientific Sessions
April 6, 2021
Sernova's Story Front-Page Nationally via Canada's Largest Newspaper Independent
March 23, 2021
Sernova Provides Positive Outlook Regarding the Development of Its Innovative Therapeutics Platform Technology for Chronic Diseases
March 15, 2021
2020 - The Emergence of Significant Scientific Medical Advances Where to Watch Next - Regenerative Medicine
March 8, 2021
Sernova Announces Closing of C$23 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option
March 1, 2021
Sernova Corp. Selected for the TSX Venture Stock Exchange's 2021 Venture 50 List of Top Performing Listed Companies
February 25, 2021
Sernova Obtains Final Prospectus Receipt for $20 Million Bought Deal
February 24, 2021
Sernova Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System(tm) Clinical Trial and Recommendation for Protocol Continuation
February 18, 2021
BTV News Alert Video: Sernova Corp. - A Functional Cure for Type I Diabetes
February 5, 2021
Sernova Upsizes Previously Announced Bought Deal Public Offering to C$20 Million
February 4, 2021
Sernova Shares Accepted for Trading on the Electronic Trading Platform Xetra in Germany
February 4, 2021
Sernova Corp. Announces C$10 Million Bought Deal Offering of Units
February 3, 2021
Sernova's Collaborator to Present Cell Pouch(TM) Thyroid Transplant Study Results at the American Association of Endocrine Surgeons 2021 Annual Meeting
February 3, 2021
(RADIO INTERVIEW) Sernova Continues to Draw Media Attention: Global News London Goes In-Depth with Dr. Philip Toleikis
February 2, 2021
Sernova Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders
January 28, 2021
Sernova Announces Warrants Exercise for Proceeds of $4.3 Million and Early Conversion of Debenture
January 25, 2021
Sernova CEO to Present Regenerative Medicine Therapeutics Platform Update at the 2021 Cell & Gene Therapy Meeting on the Med
January 21, 2021
Sernova Principal Investigator Presents Additional Positive Preliminary Safety and Efficacy Data from Ongoing U.S. Phase I/II Cell Pouch Clinical Trial for Type-1 Diabetes
January 18, 2021